NorthStrive Biosciences Partners with Charles River Laboratories to Advance Its EL-22 and EL-32 Engineered Probiotic Programs
Key Highlights
- ➤PMGC Holdings (ELAB) signed a Charles River Laboratories (CRL) analytical testing agreement
- ➤EL-22 and EL-32 testing will quantify plasmid copy numbers in engineered bacteria
- ➤Analytical data will support product identity, manufacturing consistency, and comparability
- ➤EL-22 and EL-32 advance toward an IND-enabling development framework
Expert Statements
Tara Lehner, Head of Development at NorthStrive Biosciences
“As engineered biologic products move forward in development, understanding what we are manufacturing becomes increasingly important. This work will give us quantitative analytical data around plasmid copy number and contribute to the broader characterization package we are building for EL-22 and EL-32. These are the kinds of foundational development activities that help turn an innovative platform into a reproducible and ultimately scalable pharmaceutical product.”
* Engagement of a leading global contract research organization strengthens the analytical foundation supporting EL-22 and EL-32 as the programs advance toward an IND-enabling development framework * Builds on NorthStrive Biosciences’ expanding manufacturing and characterization capabilities behind its engineered probiotic platform targeting muscle preservation, including for patients on GLP-1 weight loss treatments NEWPORT BEACH, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (Nasdaq: ELAB) (“PMGC” or the “Company”) today announced that its subsidiary, NorthStrive Biosciences Inc. (“NorthStrive Biosciences” or “NorthStrive”), has executed a Statement of Work (“SOW”) with Charles River Laboratories, Inc., NYSE: CRL (“Charles River” or “Charles River Laboratories”) to conduct analytical characterization supporting the development of NorthStrive Biosciences’ EL-22 and EL-32 engineered probiotic programs.
Get started
Create a free account to read the full story.